A 5-week randomized, placebo-controlled, double-blind study was carried out to investigate the efficacy of kava-kava special extract @entity70508 in non-psychotic nervous @entity148 , @entity2701 and restlessness states. During the first treatment week, the study dose drug was increased from 50 mg to 300 mg per day and pretreatment with @entity1245 was tapered off over 2 weeks. These dosage adjustments were followed by 3 weeks of monotherapy with @entity70508 or placebo. Outcome measures were the differences between baseline and end of treatment on the Hamilton Anxiety Scale (HAMA) and on a subjective well-being scale (Bf-S), as well as the @entity1245 withdrawal symptoms. Changes in the Erlanger Anxiety, Tension and Aggression Scale (EAAS) and Clinical Global Impressions (CGI) were analyzed as secondary measures. Treatment safety was checked by interviews, adverse event reports and laboratory investigations. Forty @entity1 (2x20) were included into the study. @entity70508 was superior to placebo regarding the HAMA (P=0.01) and Bf-S (P=0.002) total scores and all secondary efficacy measures. The tolerance of @entity70508 was not inferior to placebo. The study confirms the anxiolytic efficacy and good tolerance of @entity70508 and shows that a further symptom reduction is possible after a change-over from @entity1245 treatment.

Efficacy of kava-kava in the treatment of non-psychotic @entity148 , following pretreatment with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity70508 :: ('MESH:C488351', 'Chemical') :: ['WS1490'] @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepine', 'benzodiazepines'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity2701 :: ('MESH:D018781', 'Disease') :: ['tension']
@entity1245 :: (MESH:D001569,Chemical) :: ['benzodiazepines']
